Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11657022 | 0.79 | HIF1A (0.43) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL30084961 | 0.78 | HIF1A (0.41) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL30084976 | 0.78 | HIF1A (0.41) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL9438410 | 0.76 | LTA4H (0.43) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL11659210 | 0.76 | HIF1A (0.43) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL11657635 | 0.75 | LTA4H (0.43) | HIF1AALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL1097165 | 0.75 | HIF1A (0.46) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL4360328 | 0.75 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL11654205 | 0.74 | USP2 (0.43) | ALDH1A1TSHR | |
| Bromide SCHEMBL19809585 | 0.73 | LTA4H (0.43) | HIF1AALDH1A1CYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248161-B1 | Preparation of permanent color inks from water-soluble colorants using specific phosphonium salts | HEWLETT-PACKARD COMPANY | 2001-06-19 | — | — | US | claimed |
| US-5919552-A | Coated substrates and methods | XEROX CORPORATION (US) | 1999-07-06 | — | — | US | claimed |
| EP-0500443-B1 | Phenylethanolamino- and phenylethanolaminomethyltetralines, process for their preparation, intermediates of this process and pharmaceutical compositions containing them | SANOFI SA (FR) | 1995-04-26 | — | — | EP | claimed |
| WO-2025200154-A1 | TWO-PART EPOXY COMPOSITION COMPRISING THIOL CURATIVE, AND CATALYST | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-10-02 | — | — | WO | disclosed |
| US-20240309240-A1 | POLISHING COMPOSITION, POLISHING METHOD, AND METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE | FUJIMI INCORPORATED (JP) | 2024-09-19 | — | — | US | disclosed |
| EP-3728224-B1 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3653663-B1 | MOLDED ARTICLE AND ITS PRODUCTION METHOD | TORAY INDUSTRIES (JP) | 2022-12-28 | — | — | EP | disclosed |
| WO-2022210246-A1 | EPOXY RESIN COMPOSITION, CURED EPOXY RESIN PRODUCT, AND COATED FIBER-REINFORCED RESIN MOLDED ARTICLE OBTAINED USING SAME | 東レ株式会社 | 2022-10-06 | — | — | WO | disclosed |
| CN-113166618-B | Adhesive composition and surface protective film | DIC株式会社 | 2022-08-23 | — | — | CN | disclosed |
| US-11319315-B2 | Cyclohexyl acid triazole azoles as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| EP-2905361-B1 | METHOD OF FORMING A METAL COATING | TOYOTA MOTOR CO LTD (JP) | 2022-01-05 | — | — | EP | disclosed |
| US-6265603-B1 | FOR TREATING HUMAN CANCER | EISAI CO., LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| US-6121386-A | A SURFACE COATING TO IMPROVE OLEFIN RESIN FILMS COATABILITY E.G., ADHESION, COMPRISING A BLEND OF EPOXIDIZED BLOCK COPOLYMER OF AN AROMATIC VINYL COMPOUND AND A CONJUGATED DIENE, AND A POLYMER WITH A REACTIVE FUNCTIONAL GROUP | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-5919552-A | Coated substrates and methods | XEROX CORPORATION (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0879861-A1 | RESIN COMPOSITIONS FOR COATING | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998038162-A1 | INHIBITORS OF ISOPRENYL TRANSFERASE | EISAI CO., LTD. (JP) | 1998-09-03 | — | — | WO | disclosed |
| US-5709976-A | Coated papers | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-5449813-A | Phenylethanolamino- and phenylethanolaminomethyl-tetralines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1995-09-12 | — | — | US | disclosed |
| US-5401879-A | Phenylethanolamino- and phenylethanolaminomethyltetralines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them | SANOFI (FR) | 1995-03-28 | — | — | US | disclosed |
| US-5210276-A | PHENYLETHANOLAMINO- AND PHENYLETHANOLAMINOMETHYL-TETRALINES, PROCESS FOR THE PREPARATION THEREOF, INTERMEDIATES IN SAID PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ELF SANOFI (FR) | 1993-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319315-B2 | Cyclohexyl acid triazole azoles as LPA antagonists | LPAR3, LPAR1, LPAR2 | HIF1A 2791/4885VCP 4598/4885ALDH1A1 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.